FDA – Page 59 – Policy & Medicine

Sorrell vs. IMS Health: FDA’s Ban on Truthful Off Label Promotion May be Vulnerable

FDA: Initiative to Vet Advertising of Newly Approved Products, the Launches Program

FDA Seeks Input on Device Classification System

FDA REMS to Promote Closer Ties to Healthcare Professionals

Senator Kay Hagan Encourages FDA to Consider Faster Approval Pathway for Orphan Disease Treatments

Patient Access to Medical Innovation Act Introduced

FDA Innovation Pathway and Extension of Comment Period on Medical Device 510K Process

FDA’s Blue Print for Innovation

FDA REMS: Blue Print for Prescriber Continuing Education Program for Extended Release-Long Acting Opioids

Patient Groups Encourage Congress to Remove Burdensome FDA Rules